parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in myonuclei	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 13160

OSBPL11 in dopamine neurons, braak+0.04 (p 0.911) → -0.19 (p 0.631)receipt 13169
OSBPL11 in microglia, braak+0.93 (p 3.2e-4) → +0.14 (p 0.714)receipt 13168

receipt 13169: OSBPL11 in dopamine neurons, braak

power: full sample -0.01 (p 0.956, n 18), 95% CI -0.48 to +0.46. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.03 (p 0.894, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.07 (p 0.787, n 18). could be the mix.
skeptic: leave-one-out range -0.14 to +0.10, sign flips 5; without severely affected donors -0.01 (p 0.956, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for OSBPL11 in dopamine neurons.

case closed: nothing better to follow up.

receipt 13168: OSBPL11 in microglia, braak

power: full sample +0.51 (p 0.032, n 18), 95% CI +0.05 to +0.79. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: +0.64 (p 0.0044, n 18). holds up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.60 (p 0.0080, n 18). not the mix.
skeptic: leave-one-out range +0.44 to +0.72, sign flips 0; without severely affected donors +0.51 (p 0.032, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for OSBPL11 in microglia.

case closed: nothing better to follow up.

loading the receipts